Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food-effect Bioavailability of Gemigliptin/Dapagliflozin FDC in Healthy Volunteers
NCT05105698Phase 1Unknown
- Sponsor
- LG Chem
- Start
- Jan 2022
- Primary completion
- Feb 2022
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, open-label trial of gemigliptin + dapagliflozin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by LG Chem. Primary endpoints: Peak Plasma Concentration, Area under the plasma concentration up to the last measurable concentration and 1 more. Status: unknown.
02
Drugs
gemigliptin + dapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT05105698.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05105698.